1 March 2021 - Agios Pharmaceuticals today announced that it has submitted a Supplemental new drug application to the U.S. FDA for Tibsovo (ivosidenib) as a potential treatment for patients with previously treated isocitrate dehydrogenase 1 mutated cholangiocarcinoma.
Agios has requested priority review for the application, which, if granted, could result in a six month review process.